---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-000789"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2022-02-04T23:59:59+00:00"
generated_at: "2026-06-27T11:13:55.587446+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics director Rachel Humphrey resigns, to stay as consultant

## Summary
- Rachel Humphrey, M.D. resigned from Xilio's board effective February 3, 2022.
- Resignation was not due to any disagreement with the company or its management.
- Dr. Humphrey will continue to serve as a consultant to Xilio Therapeutics.

## SEC filing metadata
- accession: 0001558370-22-000789
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2022-02-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837022000789/0001558370-22-000789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837022000789/xlo-20220203x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-000789
- JSON: https://secwatch.observer/filing/0001558370-22-000789.json
- Plain text: https://secwatch.observer/filing/0001558370-22-000789.txt

## Key facts
- Executive change
  Rachel Humphrey resigned as director at Xilio Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: On February 3, 2022, Rachel Humphrey, M.D. notified Xilio Therapeutics, Inc. (the “Company”) of her decision to resign from the board of directors of the Company effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837022000789/0001558370-22-000789-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.